Nanoparticle-mediated delivery of FGF1 was found to enhance the engraftment and regenerative potency of transplanted human cardiomyocyte patches (hCMPs) after myocardial infarction in mice (32), while FGF1/p38 MAP kinase inhibitor treatment after acute myocardial injury in 8 to 10-week-old rats was found to induce cardiomyocyte mitosis (33). This evidence concerns the gene MAPK14 and myocardial infarction.